Mariko Harper, MD

Learn when cardiac myosin inhibitors suffice and when myectomy or alcohol ablation fits, with shared decisions at expert HCM centers.

MAPLE HCM reveals aficamten beats beta blockers in obstructive HCM, reshaping first-line therapy debates amid insurance hurdles.

Explore how aficamten’s shorter half-life enables faster titration, flexible echo monitoring, and fewer drug interactions—making HCM treatment more patient-friendly and accessible.

When beta blockers fall short in obstructive HCM, explore myosin inhibitors, disopyramide, or septal reduction—and see why patients breathe easier.

When beta blockers fall short in obstructive HCM, explore myosin inhibitors, disopyramide, or septal reduction—and learn why patients breathe easier.

Learn key hypertrophic cardiomyopathy symptoms and how echoes with Valsalva or exercise reveal hidden LVOT obstruction for accurate diagnosis.

Panelists discuss the signs, symptoms, diagnostic delays, and classification of obstructive hypertrophic cardiomyopathy, including how it differs from other forms and its implications for clinical management.

Panelists discuss the challenges and gaps in diagnosing hypertrophic cardiomyopathy, including variability in clinical practice, underdiagnosis, and opportunities to improve detection.

Martinez and Harper outline practical workflows for initiating and titrating cardiac myosin inhibitors, emphasizing multidisciplinary team structure, telemedicine, and logistics around REMS and imaging.

Martinez and Harper describe a hub-and-spoke model for HCM care, follow-up cadence, and a structured “4-pillar” framework for longitudinal management, including imaging, biomarkers, and family-based risk strategies.

Martinez and Harper review real-world REMS data on cardiac myosin inhibitors, refine approaches to safety monitoring, and question how frequently echocardiography is truly needed in stable oHCM patients.

Martinez and Harper discuss the limits of current therapies, the role of septal reduction procedures versus cardiac myosin inhibitors, and the complexities of managing younger and childbearing-age patients with oHCM.

Experts explore the concept of “gradient reduction therapy,” the remodeling effects of cardiac myosin inhibitors, and the evolving role of traditional agents in oHCM.

Experts introduce the contemporary treatment paradigm for oHCM, emphasizing earlier diagnosis, cardiac myosin inhibitor use, and objective assessment of “asymptomatic” patients.